Original articleBronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: Relationship to the development of late asthmatic responses☆
References (29)
- et al.
Plasma histamine changes during provoked bronchospasm in asthmatic patients
J Allergy Clin Immunol
(1976) - et al.
Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone diproprionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine
J Allergy Clin Immunol
(1987) - et al.
A modification of the Lowry procedure to simplify protein determi nation in membrane and lipoprotein samples
Anal Biochem
(1978) - et al.
Increased sensitivity of the enzymatic isotopic assay of histamine in plasma and serum
Anal Biochem
(1979) - et al.
Analysis of plasma histamine: a modification of the enzymatic isotopic assay
J Allergy Clin Immunol
(1986) - et al.
Measurement by radioimmunoassay of prostaglandins as their methyl oximes
Prostaglandins Leukotrienes Med
(1986) - et al.
Immunologic studies in allergen-induced late-phase asthmatic reactions
J Allergy Clin Immunol
(1984) - et al.
Mediator studies in skin-blister fluid from patients with dual skin reactions after intradermal allergen injection
J Allergy Clin Immunol
(1982) - et al.
The effect of an oral leukotriene D4 antagonist L-649,923 on the response to inhaled antigen in asthma
J Allergy Clin Immunol
(1987) - et al.
The relationship between mast cell-mediator release and bronchial reactivity in allergic asthma
J Allergy Clin Immunol
(1987)
Release of prostaglandin D2 into human airways during acute allergen challenge
N Engl J Med
Activation of pulmonary mast cells by bronchoalveolar allergen challenge: in vivo release of histamine and tryptase in atopic subjects with and without asthma
Am Rev Respir Dis
Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and control groups: an alteration in the ratio of bronchoconstrictive to bronchoprotective mediators
Am Rev Respir Dis
The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5′-monophosphate in atopic asthma
Am Rev Respir Dis
Cited by (163)
New treatments for asthma: From the pathogenic role of prostaglandin D<inf>2</inf> to the therapeutic effects of fevipiprant
2020, Pharmacological ResearchCitation Excerpt :In particular, a 150-fold increase in BALF PGD2 concentration was shown a few minutes after bronchial antigen challenge with Dermatophagoides pteronyssinus [50]. In addition, airway allergen challenge in atopic asthmatics caused a significant increase in BALF PGD2 levels when compared to atopic subjects without asthma [51]. Furthermore, in comparison to healthy individuals, CRTH2-positive cells were shown to be increased within submucosal airway tissues of patients with severe asthma [52].
COX-1 mediates IL-33–induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity
2019, Journal of Allergy and Clinical ImmunologyMast cells in airway diseases and interstitial lung disease
2016, European Journal of PharmacologyCitation Excerpt :Mast cell-derived mediators induce the classical features of the early asthmatic reaction in vivo, inducing bronchoconstriction, mucus secretion and mucosal oedema (for reviews see Bradding and Cruse (2008), Bradding et al. (2006), Brightling et al. (2003a) and Moiseeva and Bradding (2011)). For example, several studies have identified an increase in histamine, prostaglandin D2 (PGD2) and leukotriene C4 (LTC4) in the BAL fluid of asthma subjects following bronchial allergen challenge (Casale et al., 1987; Liu et al., 1991; Murray et al., 1986; Sedgwick et al., 1991; Wenzel et al., 1988, 1990, 1991) and that the early asthmatic reaction is significantly alleviated with the administration of potent selective inhibitors of histamine, LTC4 and to a lesser extent PGD2 (Beasley et al., 1987; Curzen et al., 1987; Findlay et al., 1992; Rafferty et al., 1987; Taylor et al., 1991). These mediators are most likely derived from mast cells in the bronchial mucosa because histamine, PGD2 and LTC4 are all released from human lung mast cells in vitro with remarkably similar kinetics to the allergen challenge studies (Schleimer et al., 1986).
Emerging concepts: mast cell involvement in allergic diseases
2016, Translational ResearchBiology of Mast Cells and Their Mediators
2014, Middleton's Allergy: Principles and Practice: Eighth Edition
- ☆
Supported by National Institutes of Health Grants NRSA HL-07433, HL-36577, and HL-34303.
- ∗
From the Departments of Medicine and Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colo.
- ∗∗
From the Webb-Waring Lung Institute and Cardiovascular Pulmonary Research Department, University of Colorado School of Medicine, Denver, Colo.